Ask AI · How can YK Life’s AI technology break the medical impossible triangle?

Produced by | Bullet Finance

Author | Zhang Jue

Editor | Lightning

Designer | Qianqian

Review | Songwen

As the healthcare industry has developed, the heavy asset model relying solely on physical expansion and manpower is hitting the growth ceiling. The accelerating aging population and the explosion of chronic disease management demands are driving the entire industry to reconstruct from a fragmented treatment model to a full lifecycle health management system.

For most healthcare companies, this means that the turning point of the industry or even a clearing period is approaching. How to utilize medical AI and iterative cutting-edge technologies to break through the traditional medical “high quality, broad coverage, affordable” impossible triangle has become a question that leading players must answer.

As the core listed platform of Haier Group’s health sector, YK Life has delivered its answer in this round of transformation.

After more than twenty years of transformation, YK Life has grown into a leading domestic provider of comprehensive solution services around the tumor pre-diagnosis and treatment health industry chain, offering key equipment and critical scenarios.

From the latest disclosed 2025 financial report, YK Life has maintained growth momentum even in an environment of overall industry growth slowdown.

Beyond financial data, what is more noteworthy is the structural changes behind it: the company is rapidly evolving from a comprehensive medical group driven by both medical services and medical devices to an AI-powered proactive health ecosystem platform, aiming to provide health scenario solutions as a technology company.

1. Revenue and Non-recurring Profit Both Increase, Asset Quality Continues to Optimize

In 2025, under the dual pressure of deepening healthcare payment reform and market demand fluctuations, the domestic medical service industry entered a period of deep adjustment. According to industry data, in the first three quarters of 2025, domestic private hospitals had 550 million outpatient visits, a year-on-year increase of only 0.7%, with growth nearly stagnating.

Against this backdrop, most private general hospitals and specialty chain institutions are facing growth stalls, with some leading listed companies seeing revenue growth slow to around 5% or even negative growth.

However, in the context of overall industry pressure, YK Life’s 2025 financial report shows strong growth resilience and risk resistance. During the reporting period, the company achieved operating revenue of 1.886 billion yuan, a year-on-year increase of 20.93%; net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, increased by 28.5% year-on-year.

The growth rate of non-recurring net profit significantly exceeds the revenue growth rate, directly reflecting a substantial improvement in the profitability quality of the company’s main business.

A deep dive into its revenue structure reveals that the expansion logic of YK Life’s main business is becoming increasingly clear. In 2025, the overall medical services segment of YK Life contributed over 79% of its revenue.

In terms of international layout, influenced by the expansion of overseas channels for medical devices, export revenue increased by 20.24% year-on-year, demonstrating that its medical device products are steadily gaining competitiveness in the international market.

As of the end of 2025, the company had over 1 billion yuan in sufficient cash on its books, with net cash flow from operating activities increasing by 31.47% year-on-year, providing strong financial support for its subsequent capital operations and technological research and development.

In addition, the performance fulfillment of acquired subsidiaries is an important indicator of YK Life’s further optimization of asset quality.

Taking Shengnuo Medical as an example, during the three-year commitment period from 2023 to 2025, Shengnuo Medical achieved a cumulative net profit of 87.4047 million yuan, far exceeding the performance commitment target of 68.57 million yuan, achieving a completion rate of 127.47%. In 2025 alone, Shengnuo Medical contributed operating revenue of 193 million yuan.

The successful integration of Shengnuo Medical further validates YK Life’s capabilities in acquisition management and refined operations. Within the company’s ecosystem, Shengnuo Medical continues to push for technological iterations around core products such as infusion pumps, high-pressure injectors, and breast molybdenum targets, and forms business synergies with another acquisition project, Uni Medical, to jointly expand the high-end medical market.

Additionally, YK Life successfully acquired Changsha Kexin Tumor Hospital in 2025. During the reporting period, the patient volume of this tertiary tumor specialty hospital increased by 64% year-on-year, with outpatient visits up by 95%, inpatient admissions up by 16%, and surgeries up by 38%.

Notably, YK Life has used capital reserves to offset cumulative losses, optimizing its asset-liability structure. On this basis, the company launched a cash dividend and capital reserve conversion plan, proposing to distribute a cash dividend of 0.25 yuan (including tax) for every 10 shares to all shareholders and to convert 3 shares.

This move not only solidifies capital strength but also conveys a signal to the market of its “dual improvement in quality returns.”

Looking back over the past five years, YK Life’s compound annual growth rate of operating revenue has remained at a solid level of 23.32%. In a complex and variable market environment, this continuous and stable growth momentum stems from the effectiveness of its dual-driven model of medical services and medical devices, as well as its balance between exploring existing assets and expanding incremental businesses.

2. AI Strategy Realized, Upgrading to Health Scenario Solutions

The counter-cyclical growth in performance is fundamentally a result of YK Life’s AI strategy gradually evolving from a concept to a productivity tool.

In 2025, the domestic AI medical industry entered a deep-water zone. According to Frost & Sullivan data, the market size of China’s AI medical market is expected to increase from 8.8 billion yuan in 2023 to 315.7 billion yuan in 2033, with a compound annual growth rate of 43.1%.

The application of AI technology in medicine goes far beyond imaging diagnosis; it is beginning to penetrate core areas such as decision support, drug development, and comprehensive disease management.

At this industry inflection point, YK Life views its AI strategy as a core variable for this round of leap. The company has been proactively laying out medical AI applications since 2021, and in 2024, the medical services segment began to utilize AI tools. The 2025 financial report shows that, empowered by AI, the company’s period expense ratio improved by 1.2 percentage points year-on-year.

Behind the data lies not only a steady improvement in operational efficiency but also a reconfiguration of the company’s positioning: YK Life is transforming from a comprehensive medical group driven by both medical services and devices to an AI-powered technology health solution provider.

YK Life’s AI layout shows a clear trajectory of advancement. In April 2025, the company launched the “AI Innovative Application Platform” during the 91st CMEF.

The focus of this phase is on integrating underlying systems and establishing a clinical value assessment system for AI applications, attempting to resolve the industry pain points of fragmented medical scenarios and the diversity of AI products.

Six months later, this tool-based empowerment completed its evolution into scenario-based products. In December 2025, YK Life launched the strategic product “AI Tumor Full Cycle Management Intelligent Body” in Beijing and initiated the AI Tumor Full Cycle Management Ecosystem Platform in collaboration with leading ecosystem partners such as United Imaging, Ant Group Health, and Huimei Technology.

This intelligent body covers various scenarios around the full process of tumor patients from “pre-hospital to in-hospital to post-hospital,” including precise early screening, imaging and pathological diagnosis assistance, multidisciplinary treatment decision support, home health management, and medical resource matching.

For a long time, tumor treatment has faced the challenges of information fragmentation and gaps in post-discharge care. Based on generative artificial intelligence “YK Brain,” this intelligent body achieves real-time linkage between online follow-ups and offline attending physicians.

For patients, this means having a dedicated AI personal doctor; for doctors, it provides a dynamic decision support system.

According to reports, the company’s medical services segment has achieved an approximately 80% reduction in preoperative planning time and a 10% decrease in intraoperative complication rates through AI + 3D visualization technology, while the average length of hospital stay for patients after surgery has been shortened by 1.5 days.

From an industry perspective, the large-scale commercialization of medical AI always faces numerous constraints.

On one hand, the phenomenon of “data silos” is severe, with high-quality, structured clinical datasets being extremely scarce; on the other hand, the application scenarios are “single-point,” with most current AI products concentrated in single departments or specific imaging examination sectors, lacking comprehensive support across the entire chain from pre-consultation to in-treatment intervention to post-recovery.

Due to the difficulty of entering core diagnostic flows, many medical AI tools often find themselves in awkward positions.

In contrast, YK Life’s advantage lies in having both algorithmic technical capabilities and real scenarios from multiple medical institutions, serving nearly 604,100 people annually. The deep integration of online and offline provides solutions to the challenges of data feedback and scenario closure. AI capabilities embedded in triage, diagnosis, treatment, and rehabilitation extend medical services to “full lifecycle management.”

As medical AI begins to enter deep-scale applications and reshape industry value, the traditional medical impossible triangle of “high quality, broad coverage, affordable” that is difficult to balance finally has the possibility of being broken, and this is YK Life’s vision.

3. Cutting-edge Technology Drives Neuroscience and High-end Equipment to Open Long-term Space

While deeply cultivating AI scenarios, YK Life is actively extending its reach into cutting-edge medical technology fields such as neuroscience, building a second growth curve in a more forward-looking life sciences track.

For a long time, neuroscience has been regarded as the “ultimate frontier” of human science. Industry predictions suggest that by 2030, the global scale of neuroscience-related industries will reach a trillion-dollar level. The difficulty of solving central nervous system (CNS) diseases has also led to explosive growth in the demand for diagnosis and treatment of brain-related diseases such as Parkinson’s, Alzheimer’s, and childhood autism.

Currently, the state is intensively introducing policies to support the industrialization of neuroscience and brain-computer interfaces, with neuroscience and brain-computer interfaces clearly included in the “14th Five-Year Plan” recommendations, positioned as one of the six future industries.

In 2025, the National Medical Insurance Administration released the “Guidelines for the Project Establishment of Pricing Items for Medical Services in the Nervous System (Trial),” indicating that brain-computer interface surgeries have shifted from research exploration to regular medical services, with payment channels now opened.

In this blue ocean market, YK Life is accelerating the clinical landing of cutting-edge neuroscience technologies. The Shanxi YK Life General Hospital (Yuncheng Hospital) under the company has established a mature full-process clinical system for deep brain stimulation (DBS) and has completed a total of 37 DBS implantation surgeries for Parkinson’s disease, ranking among the top in the region.

In the southwest region, YK Life’s Sichuan Friendship Hospital officially established a “Precision Diagnosis and Treatment Technology (pBFS) Clinical Application Base” in March 2026, becoming the first landing benchmark for this national-level cutting-edge therapy in the region.

The value of this technology lies in breaking the “black box” of traditional neuroscience diagnosis and treatment, based on functional magnetic resonance imaging, which can finely divide individual brain functions into over 200 functional areas, mapping out exclusive brain function circuit diagrams.

It is reported that this technology has formed a mature standardized treatment process, clinically covering four major disease categories: Parkinson’s disease, Alzheimer’s disease, autism, and speech disorders related to stroke sequelae.

Among them, the effective treatment rate for Parkinson’s disease has improved more than double compared to traditional methods, and the treatment response rate for autism can reach over 55% to 60%, filling many gaps in clinical treatment in related fields.

Currently, YK Life has translated this cutting-edge technology into specific clinical and public welfare projects, including the “Precision Rehabilitation for Children with Neurodevelopmental Disorders” launched by Sichuan Friendship Hospital and the “Precision Intervention Plan for Brain Function in Autistic Children” initiated by Qingdao Yinhai Hospital.

The reason YK Life can occupy a first-mover advantage in the wave of industrialization of neuroscience lies in the deep coupling of its clinical scenarios and technology transformation.

The iteration of neuroscience technology greatly relies on high-frequency, high-quality clinical feedback, and the nationwide medical network owned by YK Life provides a natural advantage. This capability of linking cutting-edge technology with actual hospital diagnosis and treatment not only accelerates the path from research to clinical application but also builds a high professional barrier in the field of precision neuroscience.

It is worth mentioning that while achieving breakthroughs in cutting-edge tracks such as neuroscience, YK Life continues to promote the upgrading of high-end and intelligentization in its existing medical device segment.

In 2025, the company continued to increase investment in the research and development of new-generation CT, MRI, DSA high-pressure injectors, and digital mammography systems, strengthening the construction of intelligent and domestic product lineups. While consolidating its high market share domestically, it is accelerating penetration into overseas markets such as Europe and the United States, continuously providing long-term momentum for the company’s development.

From the resilience of the financial reports of the “pre-diagnosis, treatment, and rehabilitation” full industry chain to the landing of the AI tumor full-cycle management intelligent body, and to the domestic original breakthroughs in high-end equipment and the field of neuroscience, today’s YK Life is transcending traditional medical boundaries and moving towards becoming a leading technology company, returning the proactive control of health from hospital clinics to you and me in the wave of proactive health. In the future, you will not be a passive patient but the first person responsible for your own health, and YK Life will be the intelligent partner that understands and protects you beside you.